Where is capital flowing in China's healthcare innovation in November? VCBeat's latest monthly report tracks the top deals, most active investors, and key alliances that reveal where China's healthcare ecosystem is heading next.

VCBeat's latest monthly report breaks down the top financings, most active investors, and key licensing deals to provide a data-driven navigation tool for the evolving ecosystem. Gain the clarity needed to track capital flows and partnership trends.

This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the categories of innovative pharmaceuticals and biological products, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

VCBeat's monthly ranking decodes the month's top deals, most active investors, and significant BD transactions. Get the insights to navigate the market's evolution.

An overview of China’s healthcare ecosystem in August through the lens of capital. The latest rankings of investment deals, active investors, and major BD transactions reveal where value is taking shape. Explore the trends shaping biopharma, medtech, and beyond.

An overview of China’s healthcare ecosystem in July through the lens of capital. The latest rankings of investment deals, active investors, and major BD transactions reveal where value is taking shape. Explore the trends shaping biopharma, medtech, and beyond.

This ranking highlights the latest publicly disclosed fundraising events and business development deals, offering a clear view of the evolving landscape of China's healthcare market.

This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the category of healthcare industry chain services, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the category of medical and health innovation services, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the categories of innovative pharmaceuticals and biological products, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

This ranking focuses on non-listed companies in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 evaluation committee, cross-review by supporting institutions, and final approval by an expert committee. From the categories of innovative medical devices and smart manufacturing, the top 100 innovative companies by valuation are selected (this article features the top 10 ranked companies). In addition to valuation, the growth potential and annual performance of candidate enterprises are evaluated through four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising 17 secondary metrics.